SRC
TEVA icon

Shufro Rose & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Shufro Rose & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,779
Closed -$361K – 313
2018
Q3 		$361K Sell
16,779
-100
-0.6% -$2.32K 0.03% 208
2018
Q2 		$410K Sell
16,879
-800
-5% -$16.3K 0.04% 185
2018
Q1 		$302K Sell
17,679
-40
-0.2% -$781 0.03% 226
2017
Q4 		$336K Sell
17,719
-8,225
-32% -$124K 0.03% 209
2017
Q3 		$457K Sell
25,944
-29,157
-53% -$656K 0.05% 172
2017
Q2 		$1.83M Buy
55,101
+4,780
+9% +$148K 0.2% 84
2017
Q1 		$1.61M Sell
50,321
-2,020
-4% -$68.9K 0.17% 89
2016
Q4 		$1.9M Sell
52,341
-3,494
-6% -$140K 0.21% 82
2016
Q3 		$2.57M Sell
55,835
-5,342
-9% -$279K 0.29% 73
2016
Q2 		$3.07M Sell
61,177
-688
-1% -$36.6K 0.34% 70
2016
Q1 		$3.31M Buy
61,865
+2,070
+3% +$121K 0.37% 67
2015
Q4 		$3.92M Sell
59,795
-100
-0.2% -$6.18K 0.45% 62
2015
Q3 		$3.38M Sell
59,895
-3,995
-6% -$259K 0.41% 63
2015
Q2 		$3.77M Sell
63,890
-2,670
-4% -$165K 0.4% 66
2015
Q1 		$4.15M Sell
66,560
-2,365
-3% -$138K 0.43% 67
2014
Q4 		$3.96M Sell
68,925
-2,930
-4% -$163K 0.4% 68
2014
Q3 		$3.86M Sell
71,855
-2,912
-4% -$154K 0.4% 68
2014
Q2 		$3.92M Sell
74,767
-5,726
-7% -$293K 0.4% 65
2014
Q1 		$4.25M Sell
80,493
-760
-0.9% -$35.1K 0.45% 63
2013
Q4 		$3.26M Sell
81,253
-409,841
-83% -$16.1M 0.34% 69
2013
Q3 		$18.6M Buy
491,094
+11,320
+2% +$442K 2.11% 13
2013
Q2 		$18.8M Buy
+479,774
New +$18.7M 2.23% 11

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Shufro Rose & Co's TEVA Position: Q4 2018 in Review

Shufro Rose & Co sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 16,779 shares — an estimated $361K sold.

Shufro Rose & Co first reported a position in TEVA in Q2 2013 and held it in 22 quarters. The position peaked at $18.8M in Q2 2013. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Shufro Rose & Co reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Shufro Rose & Co sold 16,779 Teva Pharmaceuticals shares in Q4 2018, an estimated $361K.
  • Shufro Rose & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • Shufro Rose & Co's Teva Pharmaceuticals position peaked at $18.8M in Q2 2013.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Shufro Rose & Co's 13F filing for Q4 2018, filed 1 Feb 2019.